IMD-0354

IMD-0354 is a small molecule inhibitor of IκB kinase β (IKKβ), which blocks the activation and nuclear translocation of NF-kappa B (NF‑κB), a key transcription factor involved in inflammation, immune response, cell proliferation, and survival. By inhibiting IKKβ-mediated phosphorylation of IκBα, IMD‑0354 prevents NF‑κB from entering the nucleus and activating target genes. This compound has demonstrated anti-inflammatory effects by reducing cytokine and chemokine production as well as adhesion molecule expression in preclinical models. It also induces G0/G1 cell cycle arrest and apoptosis in certain cancer cells. Preclinical studies have shown efficacy in models of myocardial ischemia/reperfusion injury, pulmonary arterial hypertension, allergic inflammation (asthma), breast cancer, mastocytosis, and bacterial infection (notably MRSA). A topical formulation completed phase 1 clinical trials for atopic dermatitis[3][6][7].

Other names

N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamideUNII-76145IS906UNII76145IS906UNII 76145IS906CAS 978-62-1CAS978-62-1CAS-978-62-1